AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 184 filers reported holding AERIE PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.44 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $13,898,000 | +221.3% | 575,000 | +155.6% | 2.65% | +140.2% |
| Q3 2019 | $4,325,000 | +18.7% | 225,000 | +200.0% | 1.10% | +42.4% |
| Q3 2017 | $3,645,000 | -63.5% | 75,000 | -65.9% | 0.77% | -58.4% |
| Q1 2017 | $9,977,000 | +50.6% | 220,000 | +25.7% | 1.86% | +16.6% |
| Q4 2016 | $6,624,000 | -58.7% | 175,000 | -58.8% | 1.59% | -38.7% |
| Q3 2016 | $16,040,000 | – | 425,000 | – | 2.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |